129 related articles for article (PubMed ID: 37088561)
21. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
22. Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers.
Erich SA; Constantino-Casas F; Dobson JM; Teske E
In Vivo; 2018; 32(1):7-17. PubMed ID: 29275293
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines.
Yamazaki H; Takagi S; Hoshino Y; Hosoya K; Okumura M
PLoS One; 2013; 8(11):e79810. PubMed ID: 24260303
[TBL] [Abstract][Full Text] [Related]
24. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
25. Canine histiocytic neoplasia: an overview.
Fulmer AK; Mauldin GE
Can Vet J; 2007 Oct; 48(10):1041-3, 1046-50. PubMed ID: 17987966
[TBL] [Abstract][Full Text] [Related]
26. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages.
Moore PF; Affolter VK; Vernau W
Vet Pathol; 2006 Sep; 43(5):632-45. PubMed ID: 16966440
[TBL] [Abstract][Full Text] [Related]
27. Characterization of expression and prognostic implications of GD2 and GD3 synthase in canine histiocytic sarcoma.
Murphy JD; Axiak-Bechtel S; Milner RJ; Lejeune A; Ossiboff RJ; Gell JC; Shiomitsu K
Vet Immunol Immunopathol; 2023 May; 259():110594. PubMed ID: 37058951
[TBL] [Abstract][Full Text] [Related]
28. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
29. Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.
Lenz JA; Assenmacher CA; Costa V; Louka K; Rau S; Keuler NS; Zhang PJ; Maki RG; Durham AC; Radaelli E; Atherton MJ
Cancer Immunol Immunother; 2022 Apr; 71(4):807-818. PubMed ID: 34415404
[TBL] [Abstract][Full Text] [Related]
30. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs.
Affolter VK; Moore PF
Vet Pathol; 2002 Jan; 39(1):74-83. PubMed ID: 12102221
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum ferritin as a tumor marker for canine histiocytic sarcoma.
Friedrichs KR; Thomas C; Plier M; Andrews GA; Chavey PS; Young KM
J Vet Intern Med; 2010; 24(4):904-11. PubMed ID: 20561186
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological characteristics of histiocytic sarcoma affecting the central nervous system in dogs.
Toyoda I; Vernau W; Sturges BK; Vernau KM; Rossmeisl J; Zimmerman K; Crowe CM; Woolard K; Giuffrida M; Higgins RJ; Dickinson PJ
J Vet Intern Med; 2020 Mar; 34(2):828-837. PubMed ID: 31919895
[TBL] [Abstract][Full Text] [Related]
33. Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior.
Hedan B; Thomas R; Motsinger-Reif A; Abadie J; Andre C; Cullen J; Breen M
BMC Cancer; 2011 May; 11():201. PubMed ID: 21615919
[TBL] [Abstract][Full Text] [Related]
34. Impact of palliative-intent radiotherapy with or without chemotherapy on lameness in flat coat retrievers with localised periarticular histiocytic sarcoma - a retrospective cohort, single institution study.
Odatzoglou P; Kearns T; Pittaway C; Dobson JM
Vet Comp Oncol; 2024 Mar; 22(1):22-29. PubMed ID: 37935625
[TBL] [Abstract][Full Text] [Related]
35. Clinical prognostic factors in canine histiocytic sarcoma.
Dervisis NG; Kiupel M; Qin Q; Cesario L
Vet Comp Oncol; 2017 Dec; 15(4):1171-1180. PubMed ID: 27334037
[TBL] [Abstract][Full Text] [Related]
36. Utility of the second-generation curcumin analogue RL71 in canine histiocytic sarcoma.
Kelly B; Thamm D; Rosengren RJ
Vet Res Commun; 2024 Feb; 48(1):563-568. PubMed ID: 37597087
[TBL] [Abstract][Full Text] [Related]
37. Cancer-testis antigens in canine histiocytic sarcoma and other malignancies.
Nemec PS; Kapatos A; Holmes JC; Stowe DM; Hess PR
Vet Comp Oncol; 2019 Sep; 17(3):317-328. PubMed ID: 30854786
[TBL] [Abstract][Full Text] [Related]
38. Effect of a two-base insertion mutation of the
Asada H; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
Am J Vet Res; 2019 Jul; 80(7):680-688. PubMed ID: 31246118
[TBL] [Abstract][Full Text] [Related]
39. Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma.
Asada H; Tani A; Sakuma H; Hirabayashi M; Matsumoto Y; Watanabe K; Tsuboi M; Yoshida S; Harada K; Uchikai T; Goto-Koshino Y; Chambers JK; Ishihara G; Kobayashi T; Irie M; Uchida K; Ohno K; Bonkobara M; Tsujimoto H; Tomiyasu H
Sci Rep; 2023 May; 13(1):8512. PubMed ID: 37231193
[TBL] [Abstract][Full Text] [Related]
40. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
